TECTONIC THERAPEUTIC INC
126 institutions still hold TECTONIC THERAPEUTIC INC as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
Tectonic Therapeutics Inc. (TECX, CUSIP 878972108) entered Q1 2026 with $400M of institutional 13F value across 105 institutional accounts — an appropriately concentrated holder profile for a pre-clinical-stage biotechnology company focused on regenerative medicine and tissue-engineering platforms, whose investor base consists of early-stage BIOPHARMA conviction and special-situations managers rather than diversified large-cap strategies. The defining Q1 signals: eight new positions opened in a 105-holder universe (a 7.6% holder-base expansion in a single quarter), FMR LLC added $28M, and Point72 Asset Management reduced only $8M — a near-net-positive rotation at the biotech-conviction tier that is consistent with fundamental-manager conviction building in regenerative-medicine / tissue-engineering ahead of a clinical-readout catalyst. For smart-money trackers, TECX is at the earliest institutional-coverage inflection point: the 8-new-position event in a compact holder universe is a stronger IQ signal than any dollar-size rotation, because it represents coordinated early-stage-coverage expansion by biotech specialists rather than late-stage positioning by large generalist managers.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.